Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 24:9:1042411.
doi: 10.3389/fmed.2022.1042411. eCollection 2022.

Characteristics of unvaccinated and vaccinated critically ill COVID-19 patients in calabria region (Italy): A retrospective study

Andrea Bruni  1 , Federico Longhini  1 , Sebastiano Macheda  2 , Eugenio Biamonte  1 , Pino Pasqua  3 , Giuseppe Neri  1 , Maria Laura Guzzo  4 , Eugenio Garofalo  1 ; Calabria COVID-ICU Network authors
Collaborators, Affiliations

Characteristics of unvaccinated and vaccinated critically ill COVID-19 patients in calabria region (Italy): A retrospective study

Andrea Bruni et al. Front Med (Lausanne). .

Abstract

Introduction: After the rapid surge of a novel coronavirus (SARS-CoV-2) in 2020 anti-SARS-CoV-2 vaccines have been developed to prevent the development of critical forms of COVID-19 leading to Intensive Care Unit (ICU) admission. The possibility of ICU admission after the first-cycle vaccination has been already reported; however, no data have been published regarding vaccinated patients with a "booster" dose. This retrospective study describes the characteristics of critically ill patients after the implementation of the regional "booster" dose vaccination program in a southern region of Italy.

Materials and methods: We screened all medical records of critically ill COVID-19 patients in the period between January to April 2022. We collected the demographic characteristics, the presence of comorbidities, the vaccination status, the clinical course (arterial blood gases and type of respiratory support) and outcomes (rate of tracheostomy, ICU length of stay and mortality).

Results: A total of 272 patients were admitted to ICUs during the study period. 161 patients were unvaccinated, whereas 111 were vaccinated with the complete first-cycle or "booster" dose. The type of respiratory support was similar between groups. Vaccinated patients were characterized by a better oxygenation throughout the whole ICU length of stay. Fourteen unvaccinated and 3 vaccinated patients required tracheostomy (p = 0.045). ICU length of stay was 12.2 (± 7.3) days in unvaccinated patients and 10.4 (± 6.7) days in vaccinated patients (p = 0.036). ICU mortalities were 38.5 and 24.3% in unvaccinated and vaccinated patients, respectively (p = 0.014).

Conclusion: Vaccinated patients have better clinical course and outcomes as compared to the unvaccinated population.

Keywords: COVID-19; acute respiratory failure; booster vaccination; critical care; gas exchange; vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a past co-authorship with one of the author FL.

References

    1. Cammarota G, Ragazzoni L, Capuzzi F, Pulvirenti S, De Vita N, Santangelo E, et al. Critical care surge capacity to respond to the COVID-19 pandemic in Italy: a rapid and affordable solution in the Novara Hospital. Prehosp Disaster Med. (2020) 35:431–3. 10.1017/S1049023X20000692 - DOI - PMC - PubMed
    1. Tuite AR, Ng V, Rees E, Fisman D. Estimation of COVID-19 outbreak size in Italy. Lancet Infect Dis. (2020) 20:537. 10.1016/S1473-3099(20)30227-9 - DOI - PMC - PubMed
    1. Kaji A, Koenig KL, Bey T. Surge capacity for healthcare systems: a conceptual framework. Acad Emerg Med. (2006) 13:1157–9. 10.1197/j.aem.2006.06.032 - DOI - PubMed
    1. Botta C, Indrieri A, Garofalo E, Biamonte F, Bruni A, Pasqua P, et al. COVID-19: high-JAKing of the inflammatory “flight” by ruxolitinib to avoid the cytokine storm. Front Oncol. (2020) 10:599502. 10.3389/fonc.2020.599502 - DOI - PMC - PubMed
    1. Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. (2020) 370:m2980. - PMC - PubMed